Latham & Watkins Advises SK Capital in Completed Acquisition of Valtris Specialty Chemicals
SK Capital Partners, a New York-based private investment firm focused exclusively on the specialty chemicals, materials, and pharmaceuticals sectors, has announced that its affiliates have acquired Valtris Specialty Chemicals from H.I.G. Capital. Valtris, headquartered in Independence, Ohio, is a global leader in specialty performance additives and precursors, offering innovative solutions and products to customers around the world.
Latham & Watkins represented SK Capital in the transaction with a corporate deal team led by Washington, D.C. partner Nick Luongo, with Washington, D.C. associates Brad Guest, Hilary Albrecht, Lauren Stern, Patrick Loeffler, and Kavita Satiya. Advice was also provided on finance matters by Washington, D.C. partners Jeffrey Chenard and Katherine Putnam, with Washington, D.C. associates Fitsum Tilahun, Rebecca Lamb, and Jake Goodman; on employment and benefits matters by Washington, D.C. partner Matthew Conway, London partner Catherine Drinnan, Paris partner Matthias Rubner, and Chicago partner Nineveh Alkhas, with Washington, D.C. associates Ashlie Lawton and Juliana Genova; on tax matters by Washington, D.C. partner Andrea Ramezan-Jackson, with Washington, D.C. associate Eli McCrain; on environmental, ESG, and chemical regulatory matters by Washington, D.C. partners James Barrett and Julia Hatcher, London partner Paul Davies, and London counsel Michael Green, with Washington, D.C. associate Andy Landolfi; on anti-bribery compliance/export control matters by Washington, D.C. Partner Eric Volkman, with Washington, D.C. associate Matthew Gregory; on intellectual property matters by Washington, D.C. partner Jeremiah Wolsk, with Washington, D.C. associates Ryan Clore and Lyle Stewart; on data privacy matters by Washington, D.C. partner Tony Kim, with Bay Area associate Jennifer Howes; on real estate matters by San Diego partner Robert Frances, with New York associate Thomas Ficchi; on insurance matters by Los Angeles partner Drew Levin, with Los Angeles associate Harrison White; on FDA regulatory matters by Washington, D.C. partner Elizabeth Richards, with San Diego associate Kiera Murphy; and on antitrust and foreign direct investment matters by Bay Area partner Joshua Holian, Brussels counsel Tomas Nilsson, and Hamburg counsel Jana Dammann, with Brussels associates Laia Marco and Ben Isaacs.